Contraindicated in:
Use Cautiously in:
CNS: ischemic stroke, posterior reversible encephalopathy syndrome (pres), progressive multifocal leukoencephalopathy (pml), seizures, headache, dizziness.
CV: MI, hypertension, bradycardia, heart block, peripheral edema.
Derm: MELANOMA.
EENT: macular edema.
GI: diarrhea, nausea, ↑liver enzymes.
Hemat: lymphopenia.
MS: pain.
Neuro: tremor.
Resp: pulmonary embolism, ↓ pulmonary function.
Misc: infection (including bacterial, viral and fungal).
Drug-Drug:
Patients with CYP2C9 *1/*1, *1/*2, or *2/*2 Genotype
Patients with CYP2C9 *1/*3 or *2/*3 Genotype
Absorption: Well absorbed (84%) following oral administration. Food may delay absorption.
Distribution: Extensively distributed to body tissues.
Protein Binding: >99.9%.
Metabolism/Excretion: Primarily metabolized in liver via CYP2C9 isoenzyme, with some metabolism through the CYP3A4 isoenzyme, to inactive metabolites; primarily excreted in bile/feces.
Half-life: 30 hr.
NDC Code*